Pharmacokinetics of Everolimus in Subjects With Hepatic Insufficiency
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Evaluate the pharmacokinetics of a single oral dose of everolimus in subjects with severely impaired hepatic function (Child-Pugh C) relative to healthy controls. Measure: AUC, Cmax, tmax, λz, Vd/F, CL/F and t1/2 [ Time Frame: First 8 days ]
Secondary Outcome Measures :
Evaluate the pharmacokinetics of a single oral dose of everolimus in subjects with mild and moderate impaired hepatic function (Child-Pugh A and B, respectively) relative to healthy controls. [ Time Frame: First 8 days ]
Assess the safety and tolerability of a single oral dose of everolimus in subjects with impaired hepatic function (Child-Pugh A, B, and C). [ Time Frame: First 8 days plus day 15 and day 28 post-dose follow-ups for safety ]
Explore correlation between pharmacokinetics and hepatic function parameters [ Time Frame: First 8 days ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
In good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory test values (except for values related to hepatic insufficiency).
Hepatic impaired subjects:
A Child-Pugh Classification score clinically determined as Class A, Class B, or Class C.
Absolute neutrophil count (ANC) > 1000 cells/mm3
Hemoglobin > 9 mg/mL
Platelet count > 50,000/mm3 at screening and baseline
Serum creatinine ≤ 2.0 x ULN
Free of significant medical disorders unrelated to the subject's hepatic disorder
Significant illness, including infections, or hospitalization within 4 weeks prior to dosing (hospitalization is allowed for hepatic impaired subjects if related to liver disease). Invasive systemic fungal infections need to be fully resolved prior to study entry.
History of acute or chronic bronchospastic disease (including asthma and chronic obstructive pulmonary disease, treated or not treated).
History of clinically significant drug allergy; history of atopic allergy (asthma, urticaria, eczematous dermatitis). A known hypersensitivity to the study drug (everolimus) or drugs similar to the study drug (other mTOR inhibitors, e.g., rapamycin or temsirolimus).
Active bleeding during the last 28 days prior to dosing, including variceal bleeding.
Except for hepatic impairment, any surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of drugs or which may jeopardize the subject in case of participation in the study.
Use of tobacco within 7 days prior to dosing or during the study.
Consumption of alcohol within 3 days prior to dosing or during the study.
Consumption of grapefruits, grapefruit juice, Sevilla oranges, starfruit or related foods within 7 days prior to dosing or during the study period.
Use of any drugs known to affect CYP3A4 or PgP, including both inhibitors and inducers, within 7 days prior to dosing or during the study.
Hepatic impaired subjects:
Symptoms or history of Grade 3 or 4 hepatic encephalopathy within 4 weeks of study entry.
Other protocol-defined inclusion/exclusion criteria may apply